ELMD Stock - Electromed, Inc.
Unlock GoAI Insights for ELMD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $64.00M | $54.72M | $48.07M | $41.66M | $35.76M |
| Gross Profit | $49.97M | $41.73M | $36.52M | $31.44M | $27.30M |
| Gross Margin | 78.1% | 76.3% | 76.0% | 75.5% | 76.4% |
| Operating Income | $9.66M | $6.58M | $4.01M | $2.97M | $3.14M |
| Net Income | $7.54M | $5.15M | $3.17M | $2.31M | $2.36M |
| Net Margin | 11.8% | 9.4% | 6.6% | 5.5% | 6.6% |
| EPS | $0.90 | $0.60 | $0.37 | $0.27 | $0.28 |
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 27th 2025 | Lake Street | Resumed | Buy | $36 |
| July 22nd 2025 | Roth Capital | Initiation | Buy | $29 |
| February 20th 2025 | B. Riley Securities | Initiation | Buy | $38 |
Earnings History & Surprises
ELMDEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 10, 2026 | $0.27 | — | — | — |
Q4 2025 | Nov 12, 2025 | $0.22 | $0.25 | +13.6% | ✓ BEAT |
Q3 2025 | Aug 26, 2025 | $0.22 | $0.25 | +13.6% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $0.20 | $0.21 | +5.0% | ✓ BEAT |
Q1 2025 | Feb 11, 2025 | $0.18 | $0.22 | +22.2% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $0.03 | $0.16 | +433.3% | ✓ BEAT |
Q3 2024 | Aug 27, 2024 | $0.14 | $0.20 | +42.9% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $0.13 | $0.17 | +30.8% | ✓ BEAT |
Q1 2024 | Feb 13, 2024 | $0.10 | $0.19 | +90.0% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $0.10 | $0.02 | -80.0% | ✗ MISS |
Q3 2023 | Aug 22, 2023 | $0.13 | $0.12 | -7.7% | ✗ MISS |
Q2 2023 | May 9, 2023 | $0.10 | $0.12 | +20.0% | ✓ BEAT |
Q1 2023 | Feb 14, 2023 | $0.04 | $0.11 | +214.3% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $0.04 | $0.01 | -71.4% | ✗ MISS |
Q3 2022 | Aug 23, 2022 | $0.08 | $0.04 | -50.0% | ✗ MISS |
Q2 2022 | May 10, 2022 | $0.05 | $0.07 | +40.0% | ✓ BEAT |
Q1 2022 | Feb 8, 2022 | $0.07 | $0.10 | +42.9% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $0.06 | $0.05 | -16.7% | ✗ MISS |
Q3 2021 | Aug 24, 2021 | $0.06 | $0.04 | -33.3% | ✗ MISS |
Latest News
Roth Capital Reiterates Buy on Electromed, Raises Price Target to $36
📈 PositiveElectromed Q1 EPS $0.25 Beats $0.22 Estimate, Sales $16.887M Miss $17.000M Estimate
➖ NeutralElectromed, Inc. Announces $10M Share Repurchase Authorization
📈 PositiveRoth Capital Maintains Buy on Electromed, Raises Price Target to $35
📈 PositiveLake Street Assumes Electromed at Buy, Announces Price Target of $36
📈 PositiveElectromed shares are trading higher after the company reported Q4 financial results and beat its EPS and revenue estimates.
📈 PositiveElectromed Posts 17% Gain in Fiscal Q4
📈 PositiveElectromed shares are trading higher after the company reported Q4 financial results and beat its EPS and revenue estimates.
📈 PositiveElectromed Q4 EPS $0.25 Beats $0.22 Estimate, Sales $17.39M Beat $16.64M Estimate
📈 PositiveFrequently Asked Questions about ELMD
What is ELMD's current stock price?
What is the analyst price target for ELMD?
What sector is Electromed, Inc. in?
What is ELMD's market cap?
Does ELMD pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ELMD for comparison